Keywords: Astellas, Mirabegron, OAB, Over active blader, Phase III

Astellas’ mirabegron improves key OAB symptoms in Ph III study

Article | 19 May 2011

Print This

The US subsidiary of Japanese drug major Astellas (TSE: 4503) says that the results of a pivotal Phase III clinical trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in